HCM Stock Analysis: Buy, Sell, or Hold?
HCM - HUTCHMED (China) Limited American Depositary Shares
$13.81
-0.35 (-2.47%)
▼
5d:
-0.93%
30d:
-6.18%
90d:
+1.84%
BUY
HIGH Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: Mar 23, 2026
0d
Get Alerted When HCM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: HCM trading at deep discount. Market pricing in -10.0% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: HCM trading at deep discount. Market pricing in -10.0% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$25.29
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$15.70
12.1% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HCM is currently trading at $13.81, which is considered slightly low relative to its 30-day fair value range of $13.74 to $14.75. From a valuation perspective, the stock is trading at a discount (Forward PE: 26.6) compared to its historical average (36.5). Remarkably, the market is currently pricing in an annual earnings decline of 10.0% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, HCM is showing sideways momentum. The price is currently testing key support at $13.70. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (5th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $22.85 (+65.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, HCM is showing sideways momentum. The price is currently testing key support at $13.70. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (5th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $22.85 (+65.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$13.74 -
$14.75
Company Quality Score
58/100
(HOLD)
Options IV Signal
5th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
83.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 5th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 65.5% below Wall St target ($22.85)
Fair Price Analysis
30-Day Fair Range
$13.74 -
$14.75
Current vs Fair Value
SLIGHTLY LOW
Expected Move (7 Days)
±$0.93
(6.7%)
Support & Resistance Levels
Support Level
$13.70
Resistance Level
$14.46
Current Trend
Sideways
Technical data as of
Mar 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
26.58
Wall Street Target
$22.85
(+65.5%)
Revenue Growth (YoY)
-16.5%
Earnings Growth (YoY)
-98.1%
Profit Margin
83.3%
Valuation Discount vs History
-10.0% cheaper
PE vs Historical
26.6 vs 36.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-10.0%
(market-implied from PE analysis)
1-Year Target
$12.43
(-10%)
2-Year Target
$11.19
(-19%)
3-Year Target
$10.07
(-27%)
3-Yr Target (if PE normalizes)
(PE: 27→37)
$13.82
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 26.6, Growth: 35.3%)
$34.17
(+147%)
Base:
(SPY PE: 22.4, Growth: 35.3%)
$28.79
(+109%)
Bear:
(PE: 19.0, Growth: 35.3%)
$24.47
(+77%)
📈
Valuation based on Current Earnings
Trailing PE: 5.26 | Current EPS (TTM): $2.65
Bull Case
$7.67
(-45%)
Analyst growth -50.0%, PE expands to 5.8
Base Case
$6.97
(-50%)
Market implied -50.0%, PE stable at 5.3
Bear Case
$9.48
(-32%)
Severe decline -20.0%, PE contracts to 4.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 26.6 to 36.5
Stabilization Target:
$18.96
(+37.3%)
PE Expansion Potential:
+37.3%
Share & Embed Analysis
Last updated: March 30, 2026 7:02 AM ET
Data refreshes hourly during market hours. Next update: 8:02 AM
Data refreshes hourly during market hours. Next update: 8:02 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HCM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$178 | 62 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$151 | 55 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$91 | 57 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 60 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 58 HOLD |
